Skip to main content
SpringerLink
Log in

BMS halts development of Hep C drug after death of patient

  • Media release
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Bristol-Myers Squibb Company.Bristol-Myers Squibb Discontinues Development of BMS-986094, an Investigational NS5B Nucleotide for the Treatment of Hepatitis C. Media Release: 23 Aug 2012. Available from: URL: http://www.bms.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

BMS halts development of Hep C drug after death of patient. React. Wkly. 1417, 2 (2012). https://doi.org/10.2165/00128415-201214170-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201214170-00003

Keywords

Search

Navigation